Word: waxman
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...come before the House of Representatives. California Republican William Dannemeyer plans to offer an amendment that would drastically increase the already stringent restrictions on the use of human fetuses for research purposes. A similar measure was passed by the House last year but defeated in the Senate. Congressman Henry Waxman, who opposes the amendment, argues that "fetal research saves lives, prevents or cures chronic diseases and makes pregnancy safer. As a result of such work, reductions in infant mortality and treatments for diabetes, as well as for brain disorders, are on the horizon...
...Paul Waxman, in charge of Steve's publicity, explained that advertising is "simple and non pretentious. Students were our first fans and our loyalty has always started in the colleges...
...just want to get people acquainted with our solid, wholesome product," Waxman said, adding, "then we'll leave it up to our customers to know it's the best...
...redress the problem, California Democrat Waxman last year proposed legislation that would provide financial incentives to companies undertaking or phan-drug research. Last week such bills were overwhelmingly approved by the House and the Senate. Under the provisions of the House bill, drug companies were to receive a 90% tax credit for expenses incurred in orphan-drug development, but the Senate struck this credit and substituted an appropriation of $9 million. The House measure also called for a seven-year period of exclusive marketing rights for unpatentable orphan products. It provided that in the absence of any alternative treatment, orphan...
...everyone is pleased with the legislation. In fact, the Administration issued a position paper last week opposing the measure. The statutory creation of an interagency orphan-products board, the Administration said, was superfluous be cause an equivalent panel existed within HHS. Waxman had already altered the bill to accommodate earlier Administration objections. Both the FDA and the Pharmaceutical Manufacturers Association had opposed a provision in the original bill that would have permitted approval of orphan drugs after one successful human clinical trial. With that provision dropped and other changes made, the P.M.A. now supports the bill, though it continues...